

## LITERATURA

1. Nguyen MT, Fernando S, Schwarz N, et al. Inflammation as a Therapeutic Target in Atherosclerosis. *J Clin Med*. 2019;8.
2. Mortensen Martin B, Jensen Jesper M, Rønnow Sand Niels P, et al. Association of Autoimmune Diseases With Coronary Atherosclerosis Severity and Ischemic Events. *Journal of the American College of Cardiology*. 2024;83:2643-2654.
3. Fagundes NCF, Almeida A, Vilhena KFB, et al. Periodontitis As A Risk Factor For Stroke: A Systematic Review And Meta-Analysis. *Vasc Health Risk Manag*. 2019;15:519-532.
4. Buckley DI, Fu R, Freeman M, et al. C-reactive protein as a risk factor for coronary heart disease: a systematic review and meta-analyses for the U.S. Preventive Services Task Force. *Ann Intern Med*. 2009;151:483-495.
5. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. *N Engl J Med*. 2008;359:2195-2207.
6. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. *New England Journal of Medicine*. 2017;377:1119-1131.
7. Nidorf SM, Fiolet ATL, Mosterd A, et al. Colchicine in Patients with Chronic Coronary Disease. *N Engl J Med*. 2020;383:1838-1847.
8. Tardif JC, Kouz S, Waters DD, et al. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. *N Engl J Med*. 2019;381:2497-2505.
9. Wakabayashi K, Tsujino T, Naito Y, et al. Administration of angiotensin-converting enzyme inhibitors is associated with slow progression of mild aortic stenosis in Japanese patients. *Heart Vessels*. 2011;26:252-257.
10. Bull S, Loudon M, Francis JM, et al. A prospective, double-blind, randomized controlled trial of the angiotensin-converting enzyme inhibitor Ramipril In Aortic Stenosis (RIAS trial). *Eur Heart J Cardiovasc Imaging*. 2015;16:834-841.
11. Guzik TJ, Nosalinski R, Maffia P, Drummond GR. Immune and inflammatory mechanisms in hypertension. *Nat Rev Cardiol*. 2024.
12. Czesnikiewicz-Guzik M, Osmenda G, Siedlinski M, et al. Causal association between periodontitis and hypertension: evidence from Mendelian randomization and a randomized controlled trial of non-surgical periodontal therapy. *Eur Heart J*. 2019;40:3459-3470.
13. Pietropaoli D, Cairo F, Citterio F, et al. Practical Guidelines for Patients with Hypertension and Periodontitis. *High Blood Press Cardiovasc Prev*. 2023;30:7-16.
14. Awad K, Zaki MM, Mohammed M, Lewek J, Lavie CJ, Banach M. Effect of the Renin-Angiotensin System Inhibitors on Inflammatory Markers: A Systematic Review and Meta-analysis of Randomized Controlled Trials. *Mayo Clin Proc*. 2022;97:1808-1823.
15. Lee JG, Joo SJ, Kim SY, et al. Impact of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers on clinical outcomes in hypertensive patients with acute myocardial infarction. *PLoS One*. 2023;18:e0281460.
16. Madej A, Dąbek J, Majewski M, Szuta J. Effect of perindopril and bisoprolol on IL-2, INF-γ, hs-CRP and T-cell stimulation and correlations with blood pressure in mild and moderate hypertension. *Int J Clin Pharmacol Ther*. 2018;56:393-399.
17. Ceconi C, Fox KM, Remme WJ, et al. ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT. *Cardiovascular Research*. 2007;73:237-246.
18. Strauss MH, Hall AS. Angiotensin Receptor Blockers Do Not Reduce Risk of Myocardial Infarction, Cardiovascular Death, or Total Mortality: Further Evidence for the ARB-MI Paradox. 2017;135:2088-2090.
19. Mancia G, Kreutz R, Brunström M, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). *J Hypertens*. 2023;41:1874-2071.
20. Rea F, Corrao G, Merlino L, Mancia G. Early cardiovascular protection by initial two-drug fixed-dose combination treatment vs. monotherapy in hypertension. *Eur Heart J*. 2018;39:3654-3661.

## ON-LINE KURZ

# On-line kurz Závratě

# 5 2024

### ODBORNÝ PROGRAM

- **Pacient s akutní závratí v ordinaci praktického lékaře**  
doc. MUDr. Jaroslav Jeřábek, CSc.
- **Klinické vyšetření pacienta se závratí – doporučený postup**  
MUDr. Michaela Danková
- **Polohové závratě – diagnostika a léčba** – doc. PhDr. Ondřej Čákr, Ph.D.
- **Praktická část: Demonstrace základního vyšetření závrativého pacienta a nácvik polohových manévrů BPPV**  
MUDr. Michaela Danková, doc. PhDr. Ondřej Čákr, Ph.D.

### ODBORNÝ GARANT:

doc. MUDr. Jaroslav Jeřábek, CSc.  
Neurootologické centrum  
1. a 2. LF UK v Praze, FN Motol

POČET  
KREDITŮ **2**

Registrace  
**ZDARMA**

**TERMÍN**  
březen 2024  
až únor 2025  
dostupný na  
[online.solen.cz](http://online.solen.cz)

PARTNER  
KURZU

